SecSonar.com

Cytokinetics, Incorporated (CYTK)

Cytokinetics, Incorporated at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Cytokinetics, Incorporated (CYTK) is a Biotechnology company based in US with a market capitalization of $9.5B. Revenue grew 376.6% year-over-year and free cash flow was negative at -$534.8M. This page tracks CYTK's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 498 employees · IPO Apr 30, 2004

Valuation

Valuation & price

$75.85 · as of May 17, 2026 · -13.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$86.49$59.86$33.23Jul 25Dec 25Jul 26Jul 7, 25$33.36Jul 9, 25$36.63Jul 11, 25$37.01Jul 15, 25$38.01Jul 17, 25$38.89Jul 21, 25$36.96Jul 23, 25$37.93Jul 25, 25$37.18Jul 29, 25$35.90Jul 31, 25$37.64Aug 4, 25$36.58Aug 6, 25$35.14Aug 11, 25$33.23Aug 13, 25$36.88Aug 15, 25$38.67Aug 19, 25$37.84Aug 21, 25$38.05Aug 25, 25$37.01Aug 27, 25$37.83Aug 29, 25$35.33Sep 3, 25$49.99Sep 5, 25$53.01Sep 9, 25$51.50Sep 11, 25$53.32Sep 16, 25$49.76Sep 18, 25$49.29Sep 22, 25$48.25Sep 24, 25$48.29Sep 26, 25$50.40Sep 30, 25$54.96Oct 2, 25$56.32Oct 6, 25$60.64Oct 8, 25$60.82Oct 10, 25$60.04Oct 14, 25$61.03Oct 16, 25$58.96Oct 21, 25$57.78Oct 23, 25$57.50Oct 27, 25$60.18Oct 29, 25$61.99Oct 31, 25$63.59Nov 4, 25$59.62Nov 6, 25$60.30Nov 10, 25$62.20Nov 12, 25$65.94Nov 14, 25$66.44Nov 18, 25$66.16Nov 20, 25$63.50Nov 25, 25$67.55Nov 28, 25$68.13Dec 2, 25$63.51Dec 4, 25$66.54Dec 8, 25$64.13Dec 10, 25$60.32Dec 12, 25$63.35Dec 16, 25$62.02Dec 18, 25$62.20Dec 22, 25$65.60Dec 24, 25$64.18Dec 29, 25$61.75Jan 2, 26$61.73Jan 6, 26$64.60Jan 8, 26$63.32Jan 12, 26$64.64Jan 14, 26$64.60Jan 16, 26$62.58Jan 21, 26$63.04Jan 23, 26$63.41Jan 27, 26$64.01Jan 29, 26$65.60Feb 2, 26$65.16Feb 4, 26$63.52Feb 9, 26$63.36Feb 11, 26$66.80Feb 13, 26$66.26Feb 18, 26$66.98Feb 20, 26$67.94Feb 24, 26$70.10Feb 26, 26$62.63Mar 2, 26$61.43Mar 4, 26$62.27Mar 6, 26$60.41Mar 10, 26$64.20Mar 12, 26$60.00Mar 17, 26$62.13Mar 19, 26$62.95Mar 23, 26$60.95Mar 25, 26$62.39Mar 27, 26$62.50Mar 31, 26$65.91Apr 2, 26$66.73Apr 7, 26$65.48Apr 9, 26$64.59Apr 13, 26$66.72Apr 15, 26$65.37Apr 17, 26$66.71Apr 22, 26$66.25Apr 24, 26$65.32Apr 28, 26$60.69Apr 30, 26$63.97May 4, 26$66.05May 6, 26$74.84May 8, 26$76.91May 12, 26$74.81May 14, 26$78.64May 18, 26$75.18May 20, 26$78.77May 22, 26$76.94May 28, 26$76.81Jun 1, 26$73.68Jun 3, 26$70.71Jun 5, 26$71.48Jun 9, 26$68.45Jun 11, 26$69.27Jun 15, 26$71.38Jun 17, 26$78.11Jun 22, 26$79.17Jun 24, 26$81.20Jun 26, 26$82.19Jul 2, 26$86.49
$33.2352-week range$87.26
Loading valuation history…

Fundamentals

Key fundamentals

$9.5B

Market cap

376.6%

Revenue growth (YoY)

88.5%

Gross margin

-$534.8M

Free cash flow (USD)

$402M

Net debt

7.2%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$106.4MFY 2017$13.4MFY 2018$31.5MFY 2019$26.9MFY 2020$55.8MFY 2021$70.4MFY 2022$94.6MFY 2023$7.5MFY 2024$18.5MFY 2025$88.0M
$106.4M$88M

Free cash flow by year

2016 → 2025

FY 2016$35.4MFY 2017$-104.6MFY 2018$-102.1MFY 2019$-93.5MFY 2020$-2.1MFY 2021$-191.4MFY 2022$-310.9MFY 2023$-415.7MFY 2024$-399.8MFY 2025$-534.8M
$35.4M-$534.8M

Gross margin by year

2021 → 2025

FY 2021-127.1%FY 2022-154.6%FY 2023-4284.1%FY 2024-1737.2%FY 202588.5%
-127.1%88.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

5

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $98KLee Sung · EVP, Chief Financial Officer · $97.6KJul 2, 2026Filing
  • Insider sellInsider Sell $1.3MCallos Andrew · EVP, Chief Commercial Officer · $1.3MJul 2, 2026Filing
  • Insider sellInsider Sell $3.2MLee Sung · EVP, Chief Financial Officer · $3.2MJun 29, 2026Filing
  • Insider sellInsider Sell $266KLee Sung · EVP, Chief Financial Officer · $266.4KJun 29, 2026Filing
  • Insider sellInsider Sell $278KMalik Fady Ibraham · EVP Research & Development · $278.3KJun 23, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 27, 2026Filing
  • 8-K eventCommon Stock OfferingMay 8, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • 8-K eventFDA Approval AnnouncementMay 5, 2026Filing

Questions

Frequently asked questions

What is Cytokinetics, Incorporated's market cap?

Cytokinetics, Incorporated (CYTK) has a market capitalization of $9.5B.

What is CYTK's P/E ratio?

A meaningful P/E ratio is not available for CYTK — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying CYTK stock?

SEC Form 4 filings show no open-market insider buys at Cytokinetics, Incorporated in the last 90 days (5 sells).

Same arena

Related companies in Biotechnology

KRYS

Krystal Biotech, Inc.

$9.1B

ARWR

Arrowhead Pharmaceuticals, Inc.

$10.9B

TECH

Bio-Techne Corporation

$8.1B

HALO

Halozyme Therapeutics, Inc.

$8B

IBRX

ImmunityBio, Inc.

$7.9B

MDGL

Madrigal Pharmaceuticals, Inc.

$11.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.